Search details
1.
Genomics to select treatment for patients with metastatic breast cancer.
Nature
; 610(7931): 343-348, 2022 10.
Article
in English
| MEDLINE | ID: mdl-36071165
2.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Article
in English
| MEDLINE | ID: mdl-35263519
3.
Author Correction: Genomic characterization of metastatic breast cancers.
Nature
; 572(7767): E7, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31308536
4.
Genomic characterization of metastatic breast cancers.
Nature
; 569(7757): 560-564, 2019 05.
Article
in English
| MEDLINE | ID: mdl-31118521
5.
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
Br J Cancer
; 130(4): 613-619, 2024 03.
Article
in English
| MEDLINE | ID: mdl-38182687
6.
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
Breast Cancer Res Treat
; 204(2): 249-259, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38123789
7.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast Cancer Res Treat
; 2024 Mar 07.
Article
in English
| MEDLINE | ID: mdl-38453781
8.
European value-based healthcare benchmarking: moving from theory to practice.
Eur J Public Health
; 34(1): 44-51, 2024 Feb 05.
Article
in English
| MEDLINE | ID: mdl-37875008
9.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36493792
10.
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.
Breast Cancer Res
; 25(1): 141, 2023 11 10.
Article
in English
| MEDLINE | ID: mdl-37950338
11.
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Ann Surg
; 277(1): e153-e161, 2023 Jan 01.
Article
in English
| MEDLINE | ID: mdl-33534229
12.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat
; 199(2): 371-379, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36988749
13.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34838156
14.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 380(20): 1929-1940, 2019 05 16.
Article
in English
| MEDLINE | ID: mdl-31091374
15.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Breast Cancer Res Treat
; 193(1): 95-103, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35212906
16.
Random forest of perfect trees: concept, performance, applications and perspectives.
Bioinformatics
; 37(15): 2165-2174, 2021 Aug 09.
Article
in English
| MEDLINE | ID: mdl-33523112
17.
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial.
Br J Cancer
; 124(7): 1207-1213, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33473163
18.
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Breast Cancer Res Treat
; 186(2): 417-428, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33392835
19.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 189(3): 689-699, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34414532
20.
The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients.
BMC Cancer
; 21(1): 333, 2021 Mar 31.
Article
in English
| MEDLINE | ID: mdl-33789635